N.M. Stat. § 61-11B-3
Pharmacist clinician prescriptive authority.
A. A pharmacist clinician planning to exercise prescriptive authority in practice shall
have on file at the place of practice written guidelines or protocol. The guidelines or
protocol shall authorize a pharmacist clinician to exercise prescriptive authority and
shall be established and approved by a practitioner in accordance with regulations
adopted by the board. A copy of the written guidelines or protocol shall be on file with
the board. The practitioner who is a party to the guidelines or protocol shall be in active
practice and the prescriptive authority that the practitioner grants to a pharmacist
clinician shall be within the scope of the practitioner's current practice.
B. The guidelines or protocol required by Subsection A of this section shall include:
(1)
a statement identifying the practitioner authorized to prescribe dangerous
drugs and the pharmacist clinician who is a party to the guidelines or protocol;
(2)
a statement of the types of prescriptive authority decisions that the
pharmacist clinician is authorized to make, which may include:
(a) a statement of the types of diseases, dangerous drugs or dangerous drug
categories involved and the type of prescriptive authority authorized in each case; and
(b) a general statement of the procedures, decision criteria or plan the
pharmacist clinician is to follow when exercising prescriptive authority;
(3)
a statement of the activities the pharmacist clinician is to follow in the
course of exercising prescriptive authority, including documentation of decisions made
and a plan for communication or feedback to the authorizing practitioner concerning
specific decisions made. Documentation may occur on the prescriptive record, patient
profile, patient medical chart or in a separate log book; and
(4)
a statement that describes appropriate mechanisms for reporting to the
practitioner monitoring activities and results.
C. The written guidelines or protocol shall be reviewed and shall be revised every
two years if necessary.
D. A pharmacist clinician planning to exercise prescriptive authority in practice shall
be authorized to monitor dangerous drug therapy.
E. The board shall adopt regulations to carry out the provisions of the Pharmacist
Prescriptive Authority Act.
F. For the purpose of the Pharmacist Prescriptive Authority Act, the New Mexico
medical board shall adopt rules concerning the guidelines and protocol for their
respective practitioners defined in Subsection D of Section 61-11B-2 NMSA 1978.